November 19, 2020
Nichi-Iko Pharmaceutical said on November 18 that it has filed its biosimilar version for the major cancer drug Avastin (bevacizumab) in Japan. The submission is backed by global PIII data from Spanish licenser mAbxience Research and Japanese clinical pharmacokinetics study data.read more